Mounjaro Tirzepatide Injection is an innovative once-weekly injectable medication used for the management of type 2 diabetes and weight reduction. It contains Tirzepatide, a first-in-class dual incretin receptor agonist that targets both GIP and GLP-1 receptors to improve blood sugar control and support weight loss. This dual mechanism enhances insulin secretion, reduces glucagon levels, and slows gastric emptying, helping maintain stable glucose levels and reducing appetite. Mounjaro (tirzepatide) is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg strengths.

Mounjaro 2.5 mg is typically the starting dose, allowing the body to adjust before gradually increasing the dosage as prescribed. It is administered subcutaneously using a prefilled pen, offering convenience and ease of use for patients. This medication is highly effective in lowering HbA1c levels and promoting significant weight loss when combined with a healthy diet and regular exercise.

Additionally, Mounjaro has shown benefits in improving overall metabolic health, including better insulin sensitivity and potential cardiovascular risk reduction. Its once-weekly dosing improves patient adherence compared to daily medications, making long-term treatment easier and more manageable. Regular monitoring and medical guidance are essential to achieve optimal results and minimize potential side effects.

Product Features

• Contains Tirzepatide – dual GIP and GLP-1 receptor agonist
• Once-weekly injection for convenience
• Starting dose for gradual treatment adjustment
• Supports blood sugar control and weight loss
• Easy-to-use prefilled injection pen

How It Helps

• Improves insulin secretion and lowers blood glucose
• Reduces appetite and promotes weight loss
• Lowers HbA1c levels effectively
• Supports long-term metabolic health